Literature DB >> 26655034

Procalcitonin-based algorithms to initiate or stop antibiotic therapy in critically ill patients: Is it time to rethink our strategy?

Simon W Lam1, Seth R Bauer2, Abhijit Duggal3.   

Abstract

Procalcitonin (PCT)-based antibiotic management algorithms for critically ill patients have been described in the literature. An evaluation of the available evidence demonstrates that studies have utilised PCT in various clinical scenarios: for the initiation of antimicrobials; for cessation or de-escalation of antimicrobials; or for the combination of both strategies. Current PCT reviews and meta-analyses have combined studies from all different clinical scenarios. However, there may be significant variations in algorithm compliance and clinical outcomes associated with the use of PCT in these different strategies. As such, the current review focused on separating out the studies utilising PCT in the critically ill population for different treatment strategies. Based on this review, we would recommend that PCT should not be used as the sole deciding factor for the initiation of antimicrobials. As such, PCT should not be obtained in patients who do not exhibit evidence of infection. In patients who do have signs of infection and antimicrobials have been initiated, a strategy that utilises PCT for the discontinuation or de-escalation of antimicrobials is likely to decrease the duration of treatment without adversely affecting outcome.
Copyright © 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Antibiotics; Procalcitonin; Sepsis

Mesh:

Substances:

Year:  2015        PMID: 26655034     DOI: 10.1016/j.ijantimicag.2015.10.017

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  4 in total

Review 1.  Emerging infection and sepsis biomarkers: will they change current therapies?

Authors:  Lauren Jacobs; Hector R Wong
Journal:  Expert Rev Anti Infect Ther       Date:  2016-08-17       Impact factor: 5.091

2.  A randomized trial to compare procalcitonin and C-reactive protein in assessing severity of sepsis and in guiding antibacterial therapy in Egyptian critically ill patients.

Authors:  Walid A Ali; Naglaa S Bazan; Ahmed A Elberry; Raghda R S Hussein
Journal:  Ir J Med Sci       Date:  2021-01-14       Impact factor: 1.568

3.  Ability of procalcitonin to diagnose bacterial infection and bacteria types compared with blood culture findings.

Authors:  Yuji Watanabe; Nozomi Oikawa; Maya Hariu; Ryota Fuke; Masafumi Seki
Journal:  Int J Gen Med       Date:  2016-09-30

4.  Checking procalcitonin suitability for prognosis and antimicrobial therapy monitoring in burn patients.

Authors:  Luís Cabral; Vera Afreixo; Rita Meireles; Miguel Vaz; Catarina Chaves; Marisa Caetano; Luís Almeida; José Artur Paiva
Journal:  Burns Trauma       Date:  2018-03-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.